

Manufacturer's Information Test No. 23-5840/1/2: DNA Database - Saliva

Each sample set consisted of a collection of known buccal cells from three individuals (Items 1-3), provided on either FTA[™] Indicating Micro Cards, Bode Buccal® DNA Collectors, or Puritan® Cap-Shure® swabs. Participants were requested to analyze these items using their existing protocols.

SAMPLE PREPARATION: All substrates were prepared from human buccal cheek cells suspended in sterile phosphate-buffered saline solution. The FTATM Indicating Micro Cards were spotted with 120 μ l of the cell suspension, the Bode Buccal® DNA Collectors were spotted with 200 μ l of the cell suspension, and the Puritan® Cap-Shure® swabs were spotted with 125 μ l of the cell suspension. Items 1 and 3 were created using two different male donors and Item 2 was created using a female donor. The items were prepared at separate times and were packaged once they were thoroughly dried. Completed sample sets were stored at -20°C until shipment on February 06, 2023.

SAMPLE SET ASSEMBLY: For each sample set, all Items (1-3) of the same substrate type were packaged into separate envelopes and then placed together in a pre-labeled sample set envelope and sealed. The sealed sample set envelopes were then packaged in pre-labeled heat seal envelopes and sealed. This process was repeated until all of the sample sets were prepared.

VERIFICATION: All predistribution laboratories confirmed the manufacturer's expected associations. Consistent allelic results were reported for all STR and YSTR loci across all three substrates.

Key to Test Substrates

5840 - FTA[™] Indicating Micro Cards
5841 - Bode Buccal® DNA Collectors
5842 - Puritan® Cap-Shure® Swabs

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the results that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.

Manufacturer's Information, continued Test No. 23-5840/1/2: DNA Database - Saliva

		Am	elogenin and S	STR Results							
	Results compiled from predistribution laboratories and a consensus of at least 10 participants.										
ltem	D1S1656	D2S1338	D2S441	D3\$1358	D5\$818 D65	D6S1043					
- 1	D7\$820	D8S1179 D19S433	D10S1248	D12S391	D13S317	D16S539 CSF1PO					
	D18S51		D21S11	D22S1045	Amelogenin						
	FGA	Penta D	Penta E	SE33	TH01	TPOX					
	vWA	DYS391	DYS570	DYS576	Y Indel						
1	14,17.3	16,24	14,14	14,15	12,13	*					
	11,11	12,15	16,16	19,20	12,12	9,11					
	14,18	14,15	29,31	16,16	X,Y	10,11					
	20,20	12,13	10,12	17,20.2	6,9.3	8,11					
	14,17	10	17	19	2						
2	14,15	17,25	11,11.3	16,18	11,13	*					
	8,8	13,14	13,13	17,19	11,13	12,14					
	15,16	12,14	30.2,30.2	12,15	X,X	11,12					
	20.2,25	11,12	11,11	26.2,28.2	6,9.3	8,8					
	15,17	NM	NM	NM	NM						
3	14,15	18,25	9,11.3	15,16	10,13	*					
	10,10	13,14	13,14	18,19	11,12	10,13					
	14,17	14,14	28,31.2	15,16	X,Y	12,12					
	19,21	2.2,10	7,15	27.2,30.2	9,9.3	8,9					
	16,17	10	18	18	2						

YSTR Results

Results compiled from predistribution laboratories and a consensus of at least 10 participants.									
ltem	DYF38751 DYS437 DYS518	DYS19 DYS438 DYS533	DYS385 DYS439 DYS549	DYS389-I DYS448 DYS570	DYS389-II DYS449 DYS576	DYS390 DYS456 DYS627	DYS391 DYS458 DYS635	DYS392 DYS460 DYS643	DYS393 DYS481 YGATAH4
1	35,37 14	14 12	11,14 12	13 19	29 27	25 15	10 17	13 11	13 22
	38	12	12	17	19	23	23	10	11
3	29,37 14	16 9	14,18 13	13 18	29 32	23 15	10 16	11 10	14 *
	37	12	11	18	18	21	22	12	11

* A consensus was not achieved for the loci indicated.

NM - Non-Male profile, YSTR results not expected.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the results that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.